Study guide

14.4 Immunosuppressants, Interactions and Patient Teaching

BONENT Certified Hemodialysis Nurse CHN

Track your progress as you read

Finished sections get a check mark.

1 Exam Orientation

1.1 Current CHN Exam Facts and Study Strategy

2 Chapter 1: Renal Anatomy, Physiology & CKD Pathophysiology

2.1 Nephron Physiology & Endocrine Functions 2.2 Acute Kidney Injury & Chronic Kidney Disease Staging 2.3 Fluid, Electrolyte & Acid-Base Imbalances in ESRD

3 Chapter 2: CKD-MBD, Uremia & Clinical Manifestations

3.1 CKD-Mineral and Bone Disorder (CKD-MBD) 3.2 Uremic Syndrome & Multi-System Complications 3.3 Dialysis Patient Education & Nutritional Management

4 Individualized Nursing Care

4.1 Nursing Assessment, Planning and Evaluation 4.2 Treatment Records and Safe Handoffs 4.3 Psychosocial Assessment, Counseling and Referral

5 Chapter 3: Principles of Hemodialysis & Dialysate Chemistry

5.1 Transport Mechanisms: Diffusion, Convection & Ultrafiltration 5.2 Dialyzer Characteristics, Membrane Biocompatibility & Flux 5.3 Dialysate Composition & Concentrate Formulations 5.4 Hemodialysis Adequacy: Urea Kinetics, Kt/V & URR

6 Chapter 4: Vascular Access: Fistulas, Grafts & Catheters

6.1 Arteriovenous Fistulas & Arteriovenous Grafts 6.2 Physical Examination, Surveillance & Monitoring of Access 6.3 Central Venous Catheters & CDC Infection Prevention

7 Chapter 5: Cannulation Practice & Access Complications

7.1 Cannulation Techniques: Rope-Ladder, Buttonhole & Needle Sizing 7.2 Vascular Access Stenosis, Thrombosis & Steal Syndrome 7.3 Access Infiltration, Pseudoaneurysms & Hemorrhage Management

8 Chapter 6: Hemodialysis Treatment Delivery & Circuit Monitoring

8.1 Pre-Dialysis Assessment, Target Dry Weight & UFR Limits 8.2 Extracorporeal Circuit Setup, Priming & Safety Alarms 8.3 Anticoagulation Management: Heparin Protocols & Citrate 8.4 Treatment Termination, Hemostasis & Post-Dialysis Assessment

9 Equipment and Laboratory Skills

9.1 Ancillary Equipment and Bedside Safety 9.2 Blood Sampling, Laboratory Trends and Critical Results

10 Chapter 7: Acute Intradialytic Complications & Emergencies

10.1 Intradialytic Hypotension & Muscle Cramping 10.2 Dialysis Disequilibrium Syndrome & Neurological Events 10.3 Dialyzer Reactions & Hypersensitivity (Type A and Type B) 10.4 Critical Emergencies: Air Embolism, Hemolysis & Blood Loss

11 Extended and Acute Treatment

11.1 Sequential UF, Hemofiltration and Hemoperfusion 11.2 Acute Kidney Injury and High-Risk Dialysis Initiation

12 Chapter 8: Nephrology Pharmacology in Hemodialysis

12.1 Anemia Management: ESAs & Intravenous Iron Therapy 12.2 CKD-MBD Pharmacotherapy: Binders, Vitamin D & Calcimimetics 12.3 Cardiovascular, Antimicrobial & Dialyzable Drug Dosing

13 Home and Peritoneal Dialysis

13.1 Home Dialysis Selection and Adult Learning 13.2 Home Setup, Monitoring and Emergency Readiness 13.3 Peritoneal Dialysis Principles and Nursing Care

14 Kidney Transplantation

14.1 Transplant Benefits, Burdens and Modality Counseling 14.2 Transplant Indications, Contraindications and Referral 14.3 Pretransplant Workup and Waiting-List Coordination 14.4 Immunosuppressants, Interactions and Patient Teaching 14.5 Returning to Dialysis After Graft Failure 14.6 New-Graft Monitoring and Urgent Changes

15 Chapter 9: Water Treatment Systems & Dialyzer Reprocessing

15.1 AAMI/ISO Water Treatment Architecture & Components 15.2 Chemical Contaminant Monitoring & Total Chlorine Testing 15.3 Microbiological Standards, Endotoxin Surveillance & Sampling 15.4 Dialyzer Reprocessing Standards, Testing & Germicide Safety

16 Clinical Unit Management

16.1 Evaluating Dialysis Technology and Supplies 16.2 Staffing, Personnel Policies and Standards of Care

17 Chapter 10: Supervision, Administration & Professional Practice

17.1 RN Delegation, Technician Supervision & Nurse Practice Acts 17.2 CMS Conditions for Coverage & Interdisciplinary Care Planning 17.3 Dialysis Unit Infection Control & Environmental Safety 17.4 Quality Improvement (ESRD QIP), Ethics & Palliative Care

18 Professional Development

18.1 Professional Literature, Organizations and Continuing Learning 18.2 Research Design, Implementation and Evidence Interpretation 18.3 Staff Training, Competency and Remediation

19 Environmental Hazards and Emergency Planning

19.1 Chemical Agents, Disinfection and Exposure Control 19.2 Biological Hazards and Occupational Injury Response 19.3 Fire, Threats and Power or Water Interruptions

14.4 Immunosuppressants, Interactions and Patient Teaching

Key Takeaways Explain This Topic AI

Calcineurin inhibitors require drug-level monitoring and have nephrotoxic and interaction risks.

Antimetabolites can cause cytopenias and GI effects; corticosteroids contribute to metabolic and infection risk.

Missed doses, vomiting, interactions and new infection require transplant-team guidance.

Last updated: October 2026

Why Medication Continues

The recipient's immune system can recognize donor tissue as foreign. Immunosuppressants reduce that response but do not eliminate all rejection. Regimens often combine drugs with different mechanisms to balance protection and toxicity. Induction around surgery differs from maintenance treatment, and rescue treatment for rejection is another distinct purpose. The transplant team individualizes the regimen to immunologic risk, adverse effects and graft course.

Patients need to understand that feeling well does not mean the graft no longer needs protection. Medication usually continues while the graft functions, and later reduction or withdrawal requires specialist direction. A nurse should not advise stopping therapy because the creatinine is normal, the patient has an infection or dialysis is no longer required. Those situations require assessment and a coordinated plan.

Calcineurin Inhibitors

Tacrolimus and cyclosporine inhibit calcineurin-dependent T-cell activation. They have a narrow therapeutic range and require timed drug-level monitoring. Toxicity can include kidney injury, hypertension, tremor or other neurologic symptoms, electrolyte abnormalities and metabolic effects. An increased creatinine can reflect toxicity, rejection, dehydration, obstruction or another problem; it is not automatically rejection.

Levels are interpreted in relation to the specific drug, formulation, dose timing and post-transplant phase. A trough sample is obtained before the scheduled dose according to the program's instructions. Do not take the dose first and label the later sample a trough. There is no universal target level for every recipient and every year after transplant. Different tacrolimus formulations are not casually interchangeable; dose changes require the prescriber and pharmacy process.

Antimetabolites and Other Agents

Mycophenolate inhibits lymphocyte purine synthesis and commonly causes GI symptoms and cytopenias. It also has major reproductive risks, so pregnancy planning and required precautions need specialist counseling. Azathioprine has hematologic toxicity and important interactions, notably with xanthine-oxidase inhibitors such as allopurinol; the team must review such combinations. Do not dismiss a new low white-cell count as a harmless dialysis artifact.

mTOR inhibitors such as sirolimus or everolimus have different effects, including dyslipidemia, impaired wound healing, proteinuria and cytopenias in some patients. Belatacept is a supervised infusion option for selected recipients with specific eligibility and safety considerations. The nurse needs to recognize that alternative regimens have their own risks rather than assuming every replacement is safer.

  • Drug group Monitoring/teaching priority
  • Calcineurin inhibitors Timed levels, renal function, BP, electrolytes and interactions
  • Antimetabolites Blood counts, GI tolerance and reproductive counseling
  • Corticosteroids Glucose, infection, bone health and long-term adverse effects
  • mTOR inhibitors Wound healing, lipids, blood counts and proteinuria

These are broad teaching categories. The actual drug label and transplant protocol define specific actions, doses and contraindications.

Corticosteroids and Infection Risk

Corticosteroids modify immune responses and may be used in maintenance or rejection treatment. They can increase glucose, fluid retention, BP, infection risk and bone complications. Some centers use steroid-minimizing strategies, but patients must not stop them abruptly without guidance. Teach the patient to report hyperglycemia symptoms, infection signs and medication intolerance.

Immunosuppression can blunt fever and other inflammatory findings. New cough, urinary symptoms, diarrhea, unusual fatigue or wound changes deserve prompt advice even without a high temperature. The team may prescribe antimicrobial prophylaxis, but prophylaxis does not exclude infection. Vaccines and exposure precautions follow transplant-specific recommendations; live vaccines generally require particular caution after transplantation.

Interactions and Practical Adherence

Review every prescription, over-the-counter product and supplement. Some azole antifungals, macrolides, calcium-channel blockers and other agents can alter calcineurin-inhibitor concentrations; grapefruit products can also interact. The direction and magnitude depend on the actual drug combination. Do not provide a blanket instruction to double or halve the immunosuppressant. Contact the transplant pharmacist or prescriber.

Develop a practical dosing routine, use accessible medication lists and verify refill arrangements. A missed dose, persistent vomiting or inability to obtain medicine requires prompt program contact for specific instructions. Patients should not automatically double the next dose. Explain what to do during illness and travel and whom to call outside ordinary hours. Address costs and side effects before they cause silent omission.

Scenario and Monitoring

A patient takes tacrolimus before the morning blood draw and the reported 'trough' is unexpectedly high. The nurse identifies the timing error, reports it and follows the program's repeat-sampling plan rather than independently reducing the dose. If the same patient has worsening creatinine and tremor, both the symptoms and valid drug exposure need evaluation. Good medication care joins trustworthy sampling with clinical observation.

Source: KDIGO transplant-recipient care ; current product labeling and the patient's transplant protocol govern individual dosing.